普洛药业
(000739)
| 流通市值：160.69亿 | | | 总市值：160.75亿 |
| 流通股本：11.78亿 | | | 总股本：11.79亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 3,198,046,619.86 | 11,474,162,365.59 | 8,500,085,529.08 | 5,954,455,753.01 |
| 营业收入 | 3,198,046,619.86 | 11,474,162,365.59 | 8,500,085,529.08 | 5,954,455,753.01 |
| 二、营业总成本 | 2,862,663,780.78 | 10,231,011,582.85 | 7,444,588,905.92 | 5,192,091,158.3 |
| 营业成本 | 2,429,103,622.29 | 8,529,454,580.9 | 6,223,769,938.78 | 4,370,634,067.53 |
| 税金及附加 | 8,361,997.65 | 56,089,623.61 | 37,404,446.22 | 26,880,134.62 |
| 销售费用 | 152,627,121.84 | 658,422,825.05 | 429,932,846.17 | 267,588,828.5 |
| 管理费用 | 123,254,329.94 | 466,546,668.39 | 357,913,125.93 | 244,328,917.65 |
| 研发费用 | 152,938,500.76 | 624,870,084.99 | 483,755,349.59 | 351,794,383.9 |
| 财务费用 | -3,621,791.7 | -104,372,200.09 | -88,186,800.77 | -69,135,173.9 |
| 其中:利息费用 | 8,422,207.91 | 34,230,184.64 | 27,514,388.82 | 17,208,521.63 |
| 其中:利息收入 | 10,977,859.8 | 113,471,341.33 | 67,528,122.01 | 32,615,696.93 |
| 加:公允价值变动收益 | -2,832,381.83 | -19,228.93 | -23,602,086.55 | -13,486,536.21 |
| 加:投资收益 | -2,018,356.21 | -21,684,708.02 | -3,653,320.83 | -787,930.38 |
| 资产处置收益 | 278,035.93 | 1,328,848.13 | 23,974.03 | 6,480.27 |
| 资产减值损失(新) | -30,041,951.83 | -91,833,169.24 | -60,144,046.44 | -35,918,328.51 |
| 信用减值损失(新) | -23,590,931.18 | -14,654,175.46 | 2,428,644.94 | -10,474,543.11 |
| 其他收益 | 23,121,109.72 | 103,853,603.88 | 42,975,199.1 | 7,226,674.82 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 300,298,363.68 | 1,220,141,953.1 | 1,013,524,987.41 | 708,930,411.59 |
| 加:营业外收入 | 480,645.43 | 1,423,963.54 | 2,169,085.34 | 1,291,899.61 |
| 减:营业外支出 | 1,289,063 | 16,921,855.91 | 10,999,376.45 | 2,865,274.83 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 299,489,946.11 | 1,204,644,060.73 | 1,004,694,696.3 | 707,357,036.37 |
| 减:所得税费用 | 55,775,945.03 | 149,337,162.5 | 153,380,203.03 | 106,312,915.83 |
| 六、净利润 | 243,714,001.08 | 1,055,306,898.23 | 851,314,493.27 | 601,044,120.54 |
| 持续经营净利润 | 243,714,001.08 | 1,055,306,898.23 | 851,314,493.27 | 601,044,120.54 |
| 归属于母公司股东的净利润 | 243,716,289.99 | 1,055,340,740.79 | 851,344,083.86 | 601,065,331 |
| 少数股东损益 | -2,288.91 | -33,842.56 | -29,590.59 | -21,210.46 |
| (一)基本每股收益 | 0.21 | 0.9 | 0.73 | 0.51 |
| (二)稀释每股收益 | 0.21 | 0.9 | 0.73 | 0.51 |
| 八、其他综合收益 | 743,150.25 | 2,798,837.27 | -3,095,693.43 | -3,090,949.21 |
| 归属于母公司股东的其他综合收益 | 743,150.25 | 2,798,837.27 | -3,095,693.43 | -3,090,949.21 |
| 九、综合收益总额 | 244,457,151.33 | 1,058,105,735.5 | 848,218,799.84 | 597,953,171.33 |
| 归属于母公司股东的综合收益总额 | 244,459,440.24 | 1,058,139,578.06 | 848,248,390.43 | 597,974,381.79 |
| 归属于少数股东的综合收益总额 | -2,288.91 | -33,842.56 | -29,590.59 | -21,210.46 |
| 公告日期 | 2024-04-18 | 2024-03-08 | 2023-10-19 | 2023-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |